Boston Medical Center
- Type
- Teaching hospital
- Where
- South Boston, MA
- Medicare CCN
- 220031
- Received
- $6,140,129 in 507 records, 2020 ($1,570,437 general, $4,569,692 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Boston Medical Center Corporation Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Nonprofit contractor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Patent assignee: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Trademark owner: Boston Medical Center Corporation Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 72 | $1,570,437 |
| 2020 | Research payment | 435 | $4,569,692 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 435 | $4,569,692 |
| Grant | 12 | $1,015,930 |
| Charitable Contribution | 9 | $406,206 |
| Education | 25 | $94,196 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 7 | $22,948 |
| Consulting Fee | 1 | $21,850 |
| Gift | 18 | $9,306 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Gilead Sciences, Inc. | $324,755 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-31 | Philips North America LLC | $33,974 | Research payment | Cash or cash equivalent | (6260) Ingenia 3 0T R5 Device, Neurology | 2020 | |
| 2020-12-31 | Abbott Laboratories | $33,115 | Research payment | In-kind items and services | Architect SARS-CoV-2 IgM Device, Diagnostics | Performance Evaluation of ARCHITECT SARS-CoV-2 IgM | 2020 |
| 2020-12-31 | KARL STORZ Endoscopy-America | $26,370 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | Abbott Laboratories | $18,200 | Research payment | In-kind items and services | Architect SARS-CoV-2 IgM Device, Diagnostics | Performance Evaluation of ARCHITECT SARS-CoV-2 IgM | 2020 |
| 2020-12-31 | Roche Diagnostics Operations, Inc. | $10,751 | Research payment | Cash or cash equivalent | CD cobas Reagents Device, Centralized Diagnostics | RD001469 | 2020 |
| 2020-12-31 | KARL STORZ Endoscopy-America | $8,318 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $7,346 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | Abbott Laboratories | $6,500 | Research payment | In-kind items and services | Architect SARS-CoV-2 IgM Device, Diagnostics | Performance Evaluation of ARCHITECT SARS-CoV-2 IgM | 2020 |
| 2020-12-31 | KARL STORZ Endoscopy-America | $6,090 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $5,953 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $5,600 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $4,438 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $4,084 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $3,733 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | Abbott Laboratories | $3,090 | Research payment | In-kind items and services | Architect SARS-CoV-2 IgM Device, Diagnostics | Performance Evaluation of ARCHITECT SARS-CoV-2 IgM | 2020 |
| 2020-12-31 | KARL STORZ Endoscopy-America | $2,834 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $2,691 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $2,661 | Education | In-kind items and services | 26 inch LED MONITOR Device, VIDEOIMAGING | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $2,634 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $2,634 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $2,405 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | Abbott Laboratories | $2,343 | Research payment | In-kind items and services | Architect SARS-CoV-2 IgM Device, Diagnostics | Performance Evaluation of ARCHITECT SARS-CoV-2 IgM | 2020 |
| 2020-12-31 | KARL STORZ Endoscopy-America | $2,008 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $1,746 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | Stryker Corporation | $1,366 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $1,056 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $636 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | Roche Diagnostics Operations, Inc. | $443 | Research payment | In-kind items and services | CD cobas Reagents Device, Centralized Diagnostics | RD001469 | 2020 |
| 2020-12-31 | KARL STORZ Endoscopy-America | $365 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $245 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $163 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | Abbott Laboratories | $150 | Research payment | In-kind items and services | Architect SARS-CoV-2 IgM Device, Diagnostics | Performance Evaluation of ARCHITECT SARS-CoV-2 IgM | 2020 |
| 2020-12-31 | Abbott Laboratories | $99 | Research payment | In-kind items and services | Architect SARS-CoV-2 IgM Device, Diagnostics | Performance Evaluation of ARCHITECT SARS-CoV-2 IgM | 2020 |
| 2020-12-31 | KARL STORZ Endoscopy-America | $75 | Education | In-kind items and services | 26 inch LED MONITOR Device, VIDEOIMAGING | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $74 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-31 | KARL STORZ Endoscopy-America | $25 | Education | In-kind items and services | AIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR1 | 2020 | |
| 2020-12-30 | PFIZER INC. | $15,582 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-28 | Regeneron Pharmaceuticals, Inc. | $69,143 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-12-23 | PFIZER INC. | $3,188 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $6,102 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-12-22 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2020 | |
| 2020-12-21 | Janssen Research & Development, LLC | $2,964 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-12-21 | Bayer Healthcare Pharmaceuticals Inc. | $871 | Research payment | Cash or cash equivalent | Mirena Drug, Women's Health | BAY86-5028 Mirena extension contraception | 2020 |
| 2020-12-21 | Novo Nordisk AS | $123 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-12-17 | PFIZER INC. | $8,287 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2020 | |
| 2020-12-17 | Intercept Pharmaceuticals, Inc. | $2,355 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-12-16 | PFIZER INC. | $5,783 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-15 | Merck Sharp & Dohme LLC | $2,826 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2020 |
| 2020-12-15 | Alexion Pharmaceuticals, Inc. | $2,371 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-12-15 | Alexion Pharmaceuticals, Inc. | $2,288 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-12-15 | Alexion Pharmaceuticals, Inc. | $2,275 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-12-15 | Alexion Pharmaceuticals, Inc. | $2,275 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-12-15 | Alexion Pharmaceuticals, Inc. | $2,275 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-12-15 | Alexion Pharmaceuticals, Inc. | $2,275 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-12-15 | Alexion Pharmaceuticals, Inc. | $2,275 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-12-15 | Alexion Pharmaceuticals, Inc. | $2,275 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-12-15 | Alexion Pharmaceuticals, Inc. | $1,426 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-12-14 | Merck Sharp & Dohme LLC | $118,672 | Research payment | Cash or cash equivalent | JANUVIA Drug, ENDOCRINOLOGY | Effects of SGLT2 inhibition on cardiac mitochondrial function, energetics and remodeling in non-diabetic mice with heart | 2020 |
| 2020-12-12 | PFIZER INC. | $3,188 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-11 | VERTEX PHARMACEUTICALS INCORPORATED | $11,839 | Research payment | Cash or cash equivalent | A Natural History Study of Patients With Biopsy-proven Focal Segmental Glomerulosclerosis and Proteinuria Who Are of Rec | 2020 | |
| 2020-12-11 | Novo Nordisk AS | $123 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-12-10 | Aesculap, Inc. | $3,684 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $1,023 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $586 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $490 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $430 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $313 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $245 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $188 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $185 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $175 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $168 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $143 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $92 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $81 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $70 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $35 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $26 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-09 | Emergent BioSolutions Inc. | $1,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-08 | Alexion Pharmaceuticals, Inc. | $31,598 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav | 2020 |
| 2020-12-08 | Karyopharm Therapeutics Inc. | $1,872 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | XPORT-COV-1001 | 2020 |
| 2020-12-08 | Karyopharm Therapeutics Inc. | $888 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | XPORT-COV-1001 | 2020 |
| 2020-12-07 | Abbott Laboratories | $24,949 | Research payment | In-kind items and services | Architect SARS-CoV-2 IgG Device, Diagnostics | Serum ImmunoGlobulin SIG-COVID investigation for COVID-19 healthcare workers at BMC | 2020 |
| 2020-12-04 | Adaptive Biotechnologies Corporation | $2,250 | Research payment | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | P1554 | 2020 |
| 2020-12-03 | PFIZER INC. | $10,010 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2020 | |
| 2020-12-03 | Janssen Research & Development, LLC | $3,201 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-12-02 | Novo Nordisk Inc | $75,027 | Research payment | Cash or cash equivalent | FIASP Drug, Diabetes | Comparison of post-prandial glycemic control in non-critically ill hospitalized patients with type 2 | 2020 |
| 2020-12-02 | PFIZER INC. | $22,635 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-02 | VERTEX PHARMACEUTICALS INCORPORATED | $10,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-02 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2020 | |
| 2020-12-01 | EMD Serono, Inc. | $10,400 | Research payment | Cash or cash equivalent | Tepotinib Drug, Oncology | A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic no | 2020 |
| 2020-12-01 | ViiV Healthcare Company | $6,500 | Research payment | Cash or cash equivalent | A PHASE III, RANDOMIZED, MULTICENTER, OPEN-LABEL, NON-INFERIORITY STUD | 2020 | |
| 2020-12-01 | ViiV Healthcare Company | $4,225 | Research payment | Cash or cash equivalent | A PHASE III, RANDOMIZED, MULTICENTER, OPEN-LABEL, NON-INFERIORITY STUD | 2020 | |
| 2020-12-01 | EMD Serono, Inc. | $4,225 | Research payment | Cash or cash equivalent | Tepotinib Drug, Oncology | A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic no | 2020 |
| 2020-12-01 | EMD Serono, Inc. | $2,984 | Research payment | Cash or cash equivalent | Tepotinib Drug, Oncology | A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic no | 2020 |
| 2020-12-01 | Merck Sharp & Dohme LLC | $2,662 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2020 |
| 2020-12-01 | EMD Serono, Inc. | $2,600 | Research payment | Cash or cash equivalent | Tepotinib Drug, Oncology | A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic no | 2020 |
| 2020-12-01 | EMD Serono, Inc. | $1,300 | Research payment | Cash or cash equivalent | Tepotinib Drug, Oncology | A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic no | 2020 |
| 2020-12-01 | ViiV Healthcare Company | $1,300 | Research payment | Cash or cash equivalent | A PHASE III, RANDOMIZED, MULTICENTER, OPEN-LABEL, NON-INFERIORITY STUD | 2020 | |
| 2020-12-01 | EMD Serono, Inc. | $650 | Research payment | Cash or cash equivalent | Tepotinib Drug, Oncology | A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic no | 2020 |
| 2020-11-28 | PFIZER INC. | $16,499 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-26 | Intercept Pharmaceuticals, Inc. | $4,890 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-11-25 | PFIZER INC. | $48,500 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-25 | PFIZER INC. | $2,500 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-11-24 | Novo Nordisk AS | $2,251 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-11-23 | PFIZER INC. | $96,569 | Research payment | Cash or cash equivalent | EVALUATION OF SEROTYPE 3 STRAINS COLLECTED FROM MASSACHUSETTS AND PORTUGUESE CHILDREN 20022018 | 2020 | |
| 2020-11-23 | Gilead Sciences, Inc. | $64,999 | Research payment | Cash or cash equivalent | LINC: Leveraging Informatics for NAFLD Care | 2020 | |
| 2020-11-23 | PFIZER INC. | $21,421 | Research payment | Cash or cash equivalent | EVALUATION OF SEROTYPE 3 STRAINS COLLECTED FROM MASSACHUSETTS AND PORTUGUESE CHILDREN 20022018 | 2020 | |
| 2020-11-23 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-11-23 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-11-23 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-11-23 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-11-23 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-11-21 | PFIZER INC. | $30,169 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-20 | VERTEX PHARMACEUTICALS INCORPORATED | $100,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-20 | Merck Sharp & Dohme LLC | $411 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2020 |
| 2020-11-18 | PFIZER INC. | $3,336 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2020 | |
| 2020-11-18 | Novo Nordisk Inc | $2,893 | Research payment | Cash or cash equivalent | NovoLog Drug, Diabetes | Comparison of post-prandial glycemic control in non-critically ill hospitalized patients with type 2 | 2020 |
| 2020-11-18 | Novo Nordisk Inc | $2,893 | Research payment | Cash or cash equivalent | FIASP Drug, Diabetes | Comparison of post-prandial glycemic control in non-critically ill hospitalized patients with type 2 | 2020 |
| 2020-11-17 | PFIZER INC. | $40,111 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-17 | Conformis, Inc. | $3,055 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2020 |
| 2020-11-16 | Janssen Research & Development, LLC | $50,890 | Research payment | Cash or cash equivalent | DARZALEX Biological, Oncology | A Phase I-II Trial of Daratumumab for the Treatment of Patients with AL amyloidosis | 2020 |
| 2020-11-16 | Janssen Research & Development, LLC | $440 | Research payment | Cash or cash equivalent | DARZALEX Biological, Oncology | A Phase I-II Trial of Daratumumab for the Treatment of Patients with AL amyloidosis | 2020 |
| 2020-11-10 | Merck Sharp & Dohme LLC | $2,826 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2020 |
| 2020-11-09 | Bayer Healthcare Pharmaceuticals Inc. | $3,826 | Research payment | Cash or cash equivalent | Mirena Drug, Women's Health | BAY86-5028 Mirena extension contraception | 2020 |
| 2020-11-07 | PFIZER INC. | $73,501 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-06 | Merck Sharp & Dohme LLC | $9,087 | Research payment | In-kind items and services | GARDASIL 9 Biological, VACCINE | An Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose Vaccination Regimen over 6 months Amon | 2020 |
| 2020-11-06 | Novo Nordisk AS | $41 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-11-06 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-11-05 | Alexion Pharmaceuticals, Inc. | $18,482 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav | 2020 |
| 2020-11-05 | Medical Device Business Services, Inc. | $795 | Research payment | Cash or cash equivalent | ACTIS Device, Ortho-Hip | Actis Total Hip System 2 Year Follow-up | 2020 |
| 2020-11-04 | Akcea Therapeutics, Inc. | $12,071 | Research payment | Cash or cash equivalent | IST-2019-0601: Dr. Rick Ruberg - Lumbar Spinal Stenosis surgery hATTR pt screen | 2020 | |
| 2020-11-03 | Alexion Pharmaceuticals, Inc. | $5,000 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-11-03 | Alexion Pharmaceuticals, Inc. | $5,000 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav | 2020 |
| 2020-11-03 | Alexion Pharmaceuticals, Inc. | $4,220 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-11-03 | Alexion Pharmaceuticals, Inc. | $2,600 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav | 2020 |
| 2020-11-03 | Alexion Pharmaceuticals, Inc. | $2,600 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-11-03 | Alexion Pharmaceuticals, Inc. | $2,364 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav | 2020 |
| 2020-11-03 | Alexion Pharmaceuticals, Inc. | $797 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav | 2020 |
| 2020-11-03 | Alexion Pharmaceuticals, Inc. | $650 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-10-31 | PFIZER INC. | $82,460 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-30 | Medical Device Business Services, Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DERMABOND Portfolio Device, Wound Closure | 2020 | |
| 2020-10-29 | Regeneron Pharmaceuticals, Inc. | $22,610 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-10-29 | Regeneron Pharmaceuticals, Inc. | $2,600 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-10-28 | Abbott Laboratories | $6,998 | Research payment | In-kind items and services | Architect SARS-CoV-2 IgG Device, Diagnostics | Serum ImmunoGlobulin SIG-COVID investigation for COVID-19 healthcare workers at BMC | 2020 |
| 2020-10-27 | Novo Nordisk AS | $5,495 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-10-26 | Richard Wolf Medical Instruments Corp. | $10,000 | Grant | Cash or cash equivalent | Device, Medical Center | 2020 | |
| 2020-10-26 | Janssen Research & Development, LLC | $5,005 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-10-23 | PFIZER INC. | $51,399 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-23 | Novo Nordisk AS | $246 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-10-22 | Takeda Pharmaceuticals U.S.A., Inc. | $754 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2020 |
| 2020-10-22 | Takeda Pharmaceuticals U.S.A., Inc. | $754 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2020 |
| 2020-10-22 | Takeda Pharmaceuticals U.S.A., Inc. | $754 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2020 |
| 2020-10-22 | Takeda Pharmaceuticals U.S.A., Inc. | $754 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2020 |
| 2020-10-22 | Takeda Pharmaceuticals U.S.A., Inc. | $754 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2020 |
| 2020-10-22 | Takeda Pharmaceuticals U.S.A., Inc. | $754 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2020 |
| 2020-10-22 | Takeda Pharmaceuticals U.S.A., Inc. | $78 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2020 |
| 2020-10-20 | Alexion Pharmaceuticals, Inc. | $2,288 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-10-20 | Alexion Pharmaceuticals, Inc. | $2,288 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-10-20 | Alexion Pharmaceuticals, Inc. | $2,275 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-10-20 | Alexion Pharmaceuticals, Inc. | $2,275 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-10-20 | Alexion Pharmaceuticals, Inc. | $2,275 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-10-20 | Alexion Pharmaceuticals, Inc. | $1,426 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-10-20 | Alexion Pharmaceuticals, Inc. | $1,426 | Research payment | Cash or cash equivalent | Soliris Drug, Immunology | SOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr | 2020 |
| 2020-10-19 | Regeneron Pharmaceuticals, Inc. | $75,290 | Research payment | Cash or cash equivalent | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo | 2020 | |
| 2020-10-17 | PFIZER INC. | $3,336 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2020 | |
| 2020-10-15 | Bayer Healthcare Pharmaceuticals Inc. | $956 | Research payment | Cash or cash equivalent | Mirena Drug, Women's Health | BAY86-5028 Mirena extension contraception | 2020 |
| 2020-10-15 | Bayer Healthcare Pharmaceuticals Inc. | $522 | Research payment | Cash or cash equivalent | Mirena Drug, Women's Health | BAY86-5028 Mirena extension contraception | 2020 |
| 2020-10-14 | PFIZER INC. | $70,488 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-09 | PFIZER INC. | $95,526 | Research payment | Cash or cash equivalent | BIOTHERAPEUDIC TREATMENT FOR PATIENTS WITH CHRONIC KIDNEY DISEASE AND PRETEINURIA | 2020 | |
| 2020-10-09 | Gilead Sciences, Inc. | $65,000 | Research payment | Cash or cash equivalent | Determining the Burden, Heritability, and Clinical Implications of Increased Liver Stiffness from Fatty Liver Disease in | 2020 | |
| 2020-10-09 | PFIZER INC. | $30,291 | Research payment | Cash or cash equivalent | DEVELOPING NEUTRALIZING SLIT23 MAB FOR TREATMENT OF GLOMERULAR DISEASES SUCH AS FOCAL SEGMENTAL GLOMERULOSCLEROSIS FSGS | 2020 | |
| 2020-10-07 | PFIZER INC. | $67,789 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-10-07 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2020 | |
| 2020-10-06 | Alexion Pharmaceuticals, Inc. | $12,673 | Research payment | Cash or cash equivalent | Ultomiris Drug, Immunology | A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav | 2020 |
| 2020-10-05 | Bioptics, Inc. | $8,312 | Research payment | Cash or cash equivalent | Trident Device, Breast and Skeletal Health | Trident 2.0 | 2020 |
| 2020-10-03 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2020 | |
| 2020-10-02 | Philips North America LLC | $5,368 | Research payment | Cash or cash equivalent | (7881) Ultrasound Und Device, Sleep | LFQ Phase II | 2020 |
| 2020-10-01 | Celgene Corporation | $6,609 | Research payment | Cash or cash equivalent | PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) (BMS Study Number: IM047-P23) | 2020 | |
| 2020-10-01 | Janssen Research & Development, LLC | $4,209 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-09-30 | PFIZER INC. | $88,836 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-09-30 | Abbott Laboratories | $3,900 | Research payment | In-kind items and services | Architect SARS-CoV-2 IgM Device, Diagnostics | Performance Evaluation of ARCHITECT SARS-CoV-2 IgM | 2020 |
| 2020-09-30 | Roche Diagnostics Operations, Inc. | $1,911 | Research payment | Cash or cash equivalent | CD cobas Reagents Device, Centralized Diagnostics | RD001469 | 2020 |
| 2020-09-30 | Abbott Laboratories | $300 | Research payment | In-kind items and services | Architect SARS-CoV-2 IgM Device, Diagnostics | Performance Evaluation of ARCHITECT SARS-CoV-2 IgM | 2020 |
| 2020-09-30 | Abbott Laboratories | $198 | Research payment | In-kind items and services | Architect SARS-CoV-2 IgM Device, Diagnostics | Performance Evaluation of ARCHITECT SARS-CoV-2 IgM | 2020 |
| 2020-09-29 | Merck Sharp & Dohme LLC | $2,715 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2020 |
| 2020-09-29 | E.R. Squibb & Sons, L.L.C. | $1,200 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF2 | 2020 | |
| 2020-09-29 | Novo Nordisk AS | $41 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-09-29 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-09-28 | Merck Sharp & Dohme LLC | $302 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2020 |
| 2020-09-28 | Merck Sharp & Dohme LLC | $190 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2020 |
| 2020-09-26 | PFIZER INC. | $121,349 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-09-24 | Novo Nordisk AS | $1,925 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-09-23 | Novo Nordisk AS | $360 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-09-23 | Novo Nordisk AS | $360 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-09-23 | Novo Nordisk AS | $360 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-09-23 | Novo Nordisk AS | $360 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-09-23 | Novo Nordisk AS | $360 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-09-23 | Novo Nordisk AS | $360 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
The latest 200 records of 507.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
In Massachusetts; placed by its state only.
| Measure | State Massachusetts |
|---|---|
| Population B01003 | 7,044,056 |
| Population, 2020 census P1 | 7,029,917 |
| Median age B01002 | 40.0 |
| Under 18 B01001 | 19.4% |
| 65 and over B01001 | 17.9% |
| Households B11001 | 2,785,042 |
| Foreign born B05002 | 18.0% |
| Median household income B19013 | $103,960 |
| Median family income B19113 | $131,675 |
| Per capita income B19301 | $57,897 |
| Poverty rate B17001 | 10.0% |
| Unemployment rate B23025 | 5.2% |
| Civilian labor force B23025 | 3,911,446 |
| Mean commute (minutes) B08013 | 29.1 |
| Bachelor's degree or higher B15003 | 47.3% |
| Housing units B25001 | 3,030,406 |
| Owner-occupied B25003 | 62.5% |
| Renters B25003 | 37.5% |
| Median home value B25077 | $562,100 |
| Median gross rent B25064 | $1,762 |
| White, not Hispanic B03002 | 66.6% |
| Black B03002 | 6.4% |
| Hispanic or Latino B03002 | 13.3% |
| Asian B03002 | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Massachusetts.
Comments